Shift Health Advisory, LLC

Business Insights

Simulations Plus, Inc. | July 04, 2022

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual content delivery for the 2022 Pharmacometrics Spring School using MonolixSuite™. New for 2022 was the introduction of the “NCA, bioequivalence, and beyond! Spring School” course using PKanalix™. Both workshops were held in March 2022. This year’s Spring Schools fo...

Business Insights

Adalvo | March 01, 2022

Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM a venture initiated in close collaboration with SK Pharma. Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs. ArphioTM will operate as an independent entity, focus...

Movilitas | September 11, 2020

Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while imp...

Practice Management

Farxiga | January 07, 2021

Pushing for another endorsement for SGLT2 prescription Farxiga in persistent kidney illness (CKD), AstraZeneca a year ago posted amazing information in its critical preliminary. Presently, the FDA has acknowledged its CKD application and granted a need survey, setting up a choice for the subsequent quarter—and putting Farxiga significantly farther in front of its future adversaries. In that preliminary, named Dapa-CKD, AZ's Farxiga in addition to standard of care cut the...